New User:
-or-
Username:
Password:
Forgot your password?
News Breaks
08:09 EDTPTIE
theflyonthewall.com: Pain Therapeutics Remoxy still in-line to be first to market, says Gabelli
Gabelli still believes that Pain Therapeutics' (PTIE) Remoxy will be the first long-acting oxycodone with abuse deterrent features to be approved with a differentiated label. The firm thinks that Purdue Pharmaceutical's Oxycotin, a potential competitor, will have to undergo much more scrutiny by the FDA. The firm maintains a Buy rating on Pain Therapeutics. :theflyonthewall.com



News For PTIE From The Last 14 Days
Check below for free stories on PTIE the last two weeks.
There are 2 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 2, 2010
16:21 EDTPTIE
theflyonthewall.com: Pain Therapeutics files $150M mixed securities shelf
:theflyonthewall.com

January 28, 2010
08:56 EDTPTIE
theflyonthewall.com: Pain Therapeutics reports Q4 EPS (1c) vs. consensus of (4c)

Subscribe for More Information :theflyonthewall.com